Business context and reporting period
Filing identity: The supplied filing is Eliem Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022; it is not a Climb Bio filing. Eliem is a clinical-stage biotechnology company developing therapies for neuronal excitability disorders. It had no approved products and generated no product revenue.
Financial performance and position
Amounts below are in millions of dollars, except per-share data. Revenue and operating margins are not applicable because the company had no product sales.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $4.3 | $6.0 | $21.3 | $16.4 |
| General and administrative expense | $4.5 | $3.4 | $14.3 | $8.5 |
| Total operating expenses | $8.7 | $9.4 | $35.6 | $25.0 |
| Net loss | $9.7 | $9.6 | $37.5 | $36.9 |
| Net loss per share | $0.37 | $0.70 | $1.43 | $5.49 |
| Cash used in operating activities | Not stated for quarter | Not stated for quarter | $28.9 | $28.2 |
At September 30, 2022, cash and cash equivalents were $35.9 million and marketable securities totaled $93.6 million, or $129.6 million of cash and investments combined. Total assets were $140.9 million, total liabilities $6.5 million, and stockholders’ equity $134.4 million. The filing reports no debt. Current assets of $133.2 million compared with current liabilities of $6.3 million. Accumulated deficit was $113.1 million.
Material changes versus prior comparable periods
- Q3 research and development expense declined 28.9%, mainly reflecting lower clinical and preclinical costs, ETX-810 discontinuation, the delayed ETX-155 MDD trial, and a $1.5 million reversal of clinical expense accruals. Lower U.K. R&D tax credits partly offset the expense reduction.
- Q3 general and administrative expense rose 32.3%, largely from increased headcount, stock-based compensation, insurance, consulting, and legal costs.
- For the first nine months, R&D expense increased 29.5% and G&A increased 67.7%, reflecting program activity and higher personnel and public-company costs.
- Nine-month operating cash use was broadly similar year over year. Investing activities provided $20.2 million in 2022, primarily from marketable-security maturities net of purchases; 2021 included substantial investment purchases. No financing cash was raised in the first nine months of 2022, compared with $177.2 million in 2021 from preferred-stock sales and the IPO.
- Cash and investments declined from $161.4 million at December 31, 2021 to $129.6 million at September 30, 2022. The company adopted lease accounting in 2022 and recorded operating lease assets and liabilities.
Outlook, risks, contingencies and unusual items
- Management estimated the September 30 cash and investments would fund operations into 2025 under its current plan; the liquidity note separately states sufficiency for at least 12 months from filing. Both estimates rely on assumptions and additional funding will be required to develop and potentially commercialize the pipeline.
- Management planned to initiate the ETX-155 Phase 2a major depressive disorder trial in Q1 2023 using a 60 mg dose, with topline results expected in H2 2024. Eliem decided not to restart the photosensitive epilepsy proof-of-concept trial; it planned further work on a modified-release formulation for focal-onset seizures in 2023.
- The preclinical Kv7.2/3 program was advancing toward IND-enabling safety studies in Q1 2023 and planned Phase 1 studies in H1 2024. Eliem discontinued early development of an anxiolytic program after compounds failed to meet the required profile. ETX-810 was discontinued after two Phase 2a trials failed their primary endpoints.
- Q3 foreign-currency loss was $1.3 million; nine-month loss was $2.5 million, mainly from pound-to-dollar movements affecting U.K. R&D tax-credit balances. Interest income increased with higher investment returns. The 2021 comparative period included an $11.7 million noncash charge related to settlement of a preferred-stock tranche liability.
- Key risks include clinical and regulatory failure or delay, reliance on third-party trial and manufacturing providers, need for additional capital, foreign-exchange exposure, and potential COVID-19-related disruptions. Management said pandemic-related supply and vendor delays had not materially affected the business to date.
- Disclosure controls were deemed ineffective at September 30, 2022 because of material weaknesses involving accounting staffing and expertise, formal accounting controls and segregation of duties, and IT general controls. Remediation efforts were underway; management stated the weaknesses had not caused a financial-statement misstatement.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material minimum purchase commitments under its third-party service contracts.
Important facts for investors to verify
- Confirm the issuer: this document identifies Eliem Therapeutics, Inc. (ticker ELYM), despite the request metadata naming Climb Bio.
- Track ETX-155 Phase 2a MDD trial initiation, dose selection, enrollment, and timing of topline results against management’s stated schedule.
- Assess whether the planned focal-onset seizure formulation and Kv7.2/3 program meet their development milestones.
- Monitor cash burn, investment balances, funding needs, and whether the projected runway into 2025 remains achievable.
- Review progress and independent testing of remediation for the disclosed internal-control material weaknesses.
- Consider the $1.5 million clinical-accrual reversal and the impact of foreign-exchange movements and U.K. tax credits when interpreting quarterly R&D expense and loss.